Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2007
10/17/2007EP1845099A1 Artemisine (qinghaosu) derivatives, their preparation methods and their use, and pharmaceutical compositions containing the same
10/17/2007EP1845098A1 Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
10/17/2007EP1845097A1 Oxadiazole derivatives as COMT inhibitors
10/17/2007EP1845096A1 12-Aza-epothilones, process for their preparation and their use as antiproliferative agents
10/17/2007EP1845095A1 1-thio-d-glucitol derivatives
10/17/2007EP1845094A1 Method of tumor suppression and evaluation of anticancer agent based on gsk3 beta inhibitory effect
10/17/2007EP1845093A1 A new crystalline and stable form of andolast
10/17/2007EP1845092A1 Pyrimidinone compounds, their preparation and use thereof
10/17/2007EP1845091A1 Process for producing muscarine receptor antagonist and intermediate therefor
10/17/2007EP1845090A1 Amide compound and thrombopoietin receptor activator
10/17/2007EP1845089A1 Novel lactams and uses thereof
10/17/2007EP1845088A1 An improved process for the preparation of aripipirazole
10/17/2007EP1845084A1 Process for producing (z)-1-phenyl-1-(n,n-diethylaminocarbonyl)idomethylcyclopropane
10/17/2007EP1845083A2 New arylsulfonohydrazide inhibitors of enzymes MurC and MurD
10/17/2007EP1845082A1 New strontium salts of sulphonic acids, preparation method and pharmaceutical compositions containing them
10/17/2007EP1844794A1 Silicon implants comprising a radionucleotide and/or a cytotoxic drug and their use in cancer treatment
10/17/2007EP1844792A1 Therapeutic agent for constipation
10/17/2007EP1844787A1 Drugs for nerve cell regeneration
10/17/2007EP1844784A1 A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system
10/17/2007EP1844783A1 Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel - subunit Nav1.6
10/17/2007EP1844782A1 Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel subunit Nav1.6
10/17/2007EP1844781A1 Use of sodium channel blockers for the treatment of preterm labor
10/17/2007EP1844780A2 Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone
10/17/2007EP1844779A2 Tergurid/protergurid for treating chronic pain (e.g. migraine)
10/17/2007EP1844778A1 Agent for prevention/therapy of disease caused by keratinocyte growth
10/17/2007EP1844777A1 Chronic, bolus administration of d-treo methylphenidate
10/17/2007EP1844776A1 Agent for prevention/treatment of disease caused by acyclovir-resistant herpesvirus
10/17/2007EP1844775A1 Therapeutic agent for herpes progenitalis
10/17/2007EP1844774A2 A pharmaceutical composition for angiotensin II-mediated diseases
10/17/2007EP1844773A1 Percutaneous absorption preparation
10/17/2007EP1844772A1 Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
10/17/2007EP1844771A2 Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
10/17/2007EP1844770A1 Tablets containing ornithine hydrochloride
10/17/2007EP1844769A2 Methods for treating neuropsychiatric disorders
10/17/2007EP1844768A1 Aromatic sulfone compound as aldosterone receptor modulator
10/17/2007EP1844767A2 Epoxide hydrolase complexes and methods therewith
10/17/2007EP1844766A2 Inhibitors against the production and release of inflammatory cytokines
10/17/2007EP1844765A1 Contraception and hormone replacement therapy comprising a combination of estrogene with cholesterol and progesterone
10/17/2007EP1844763A1 Percutaneously absorbable preparation, percutaneously absorbable preparation holding sheet, and percutaneously absorbable preparation holding equipment
10/17/2007EP1844734A2 Combination drug therapy for reducing scar tissue formation
10/17/2007EP1844201A2 Aqueous gel formulations containing immune response modifiers
10/17/2007EP1844148A2 Nucleic acid silencing of huntington's disease gene
10/17/2007EP1844146A2 Cosmetic or pharmaceutical preparations containing nucleic acids having sequences suited for forming stem-loop secondary structures
10/17/2007EP1844131A1 Process for the preparation of fatty acids
10/17/2007EP1844063A1 Purine nucleoside analogs
10/17/2007EP1844062A2 Inhibitors of dna methyltransferase
10/17/2007EP1844055A1 Anthelmintic imidazol-thiazole derivatives
10/17/2007EP1844054A2 Thiazolopyrimidine compounds for the modulation of chemokine receptor activity
10/17/2007EP1844053A2 Anti-inflammatory macrolide conjugates
10/17/2007EP1844052A1 Thieno[2,3-d]pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
10/17/2007EP1844051A1 Thienopyrroles useful in the treatment of inflammation
10/17/2007EP1844050A1 Pyrrolopyrimidines useful as inhibitors of protein kinase
10/17/2007EP1844048A1 Pyrazolopyrimidines as cell cycle kinase inhibitors
10/17/2007EP1844047A1 Hydrate of n-methyl-n-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]- pyramidin-7-yl}phenyl)acetamide and processes and methods related thereto
10/17/2007EP1844046A1 Novel indolopyridines, benzofuranopyridines and benzothienopyridines
10/17/2007EP1844045A1 Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors
10/17/2007EP1844044A1 Thiazole-4-carboxamide derivatives as mglur5 antagonists
10/17/2007EP1844042A1 Indole derivatives for treating viral infections
10/17/2007EP1844040A1 Crystalline forms of cis-5-fluoro-n-[4-(2-hydroxy-4-methylbenzamido)cyclohexyl]-2-(tetrahydrothiopyran-4-yloxy)nicotinamide
10/17/2007EP1844039A1 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics
10/17/2007EP1844037A1 Chemical compounds
10/17/2007EP1844036A1 Salts of aripiprazole
10/17/2007EP1844035A1 Amino-pyridines as inhibitors of beta-secretase
10/17/2007EP1844034A1 Dnt-fumarate and methods of preparation thereof
10/17/2007EP1844032A1 N-hydroxyamide derivatives and use thereof
10/17/2007EP1844031A1 Substituted phenyl-piperazine compounds, their preparation and use in medicaments
10/17/2007EP1844030A1 Cyclohexylamides as dopamine d3 , d2 and 5ht1a antagonists
10/17/2007EP1844029A1 Novel heterocyclic oxime derivatives, method for preparing same and use thereof as hypoglycaemic or hypolipidemic agents
10/17/2007EP1844028A1 MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
10/17/2007EP1844027A1 Thiazolidinones for use as inhibitors of polo-like kinase (plk)
10/17/2007EP1844026A2 Morpholines as 5ht2c agonists
10/17/2007EP1844023A1 Quinazoline derivatives for the treatment and prevention of diabetes and obesity
10/17/2007EP1844021A1 Crystalline forms of rosuvastatin calcium salt
10/17/2007EP1844020A1 Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
10/17/2007EP1844018A2 Crystalline forms fenoldopam mesylate
10/17/2007EP1844016A1 Polymorph and solvates of aripiprazole
10/17/2007EP1844015A2 Novel heterocyclic oxime derivatives, method for preparing same and pharmaceutical compositions containing same
10/17/2007EP1844013A1 Indoles useful in the treatment of inflammation
10/17/2007EP1844011A1 2-phenyl-indoles as prostaglandin d2 receptor antagonists
10/17/2007EP1844009A1 Compositions and methods for treating cardiovascular disorders
10/17/2007EP1844008A1 Valnemulin salts with organic acids
10/17/2007EP1844006A2 Taurine synthesis, production and utility as a medicine
10/17/2007EP1844004A1 Quinazoline derivates as antiviral agents
10/17/2007EP1844003A1 Novel biaromatic compounds, inhibitors of the p2x7-receptor
10/17/2007EP1844002A1 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
10/17/2007EP1844001A1 Metabolites of 2-arylpropionic acid derivatives and pharmaceutical compositions containing them
10/17/2007EP1844000A1 Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
10/17/2007EP1843999A1 Process for preparing tolterodine tartrate
10/17/2007EP1843820A1 Multicyclic bis-amide mmp inhibitors
10/17/2007EP1843791A1 Treatment of degenerative diseases with the x-linked inhibitor of apoptosis
10/17/2007EP1843789A2 Compositions and methods for treating fibrotic disorders
10/17/2007EP1843778A1 Compositions comprising epigallocatechin gallate and protein hydrolysate
10/17/2007EP1843773A1 Method and composition for treatment of neoplasms
10/17/2007EP1843772A1 Intravenous formulations of pde-5 inhibitors
10/17/2007EP1843771A2 Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
10/17/2007EP1843770A2 Solid particulate tadalafil having a bimodal particle size distribution
10/17/2007EP1843769A1 Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
10/17/2007EP1843768A2 Substituted morphinans and methods of their use
10/17/2007EP1843767A1 2,5-disubstituted phenyl methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders.
10/17/2007EP1843766A1 Antidiabetic bicyclic compounds
1 ... 3542 3543 3544 3545 3546 3547 3548 3549 3550 3551 3552 3553 3554 3555 3556 3557 3558 3559 3560 3561 3562 ... 7860